Cannapharmarx Stock Return On Equity
| CPMD Stock | USD 0 0 45.45% |
Fundamental analysis of CannaPharmaRx allows traders to better anticipate movements in CannaPharmaRx's stock price by examining its financial health and performance throughout various phases of its business cycle.
CannaPharmaRx |
CannaPharmaRx Company Return On Equity Analysis
CannaPharmaRx's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current CannaPharmaRx Return On Equity | -2.51 |
Most of CannaPharmaRx's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CannaPharmaRx is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, CannaPharmaRx has a Return On Equity of -2.5089. This is 89.53% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Did you try this?
Run Price Ceiling Movement Now
Price Ceiling MovementCalculate and plot Price Ceiling Movement for different equity instruments |
| All Next | Launch Module |
CannaPharmaRx Fundamentals
| Return On Equity | -2.51 | |||
| Return On Asset | -0.26 | |||
| Current Valuation | 20.13 M | |||
| Shares Outstanding | 257.57 M | |||
| Shares Owned By Insiders | 1.12 % | |||
| Price To Book | 11.05 X | |||
| EBITDA | (6.07 M) | |||
| Net Income | (8.83 M) | |||
| Cash And Equivalents | 5.18 K | |||
| Total Debt | 14.96 M | |||
| Debt To Equity | 7.05 % | |||
| Book Value Per Share | (0.07) X | |||
| Cash Flow From Operations | (2.41 M) | |||
| Earnings Per Share | (0.12) X | |||
| Beta | 0.21 | |||
| Market Capitalization | 2.83 M | |||
| Total Asset | 114.33 K | |||
| Retained Earnings | (28.64 M) | |||
| Working Capital | (285 K) | |||
| Current Asset | 233 K | |||
| Current Liabilities | 518 K | |||
| Net Asset | 114.33 K |
About CannaPharmaRx Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CannaPharmaRx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CannaPharmaRx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CannaPharmaRx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in CannaPharmaRx Pink Sheet
CannaPharmaRx financial ratios help investors to determine whether CannaPharmaRx Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CannaPharmaRx with respect to the benefits of owning CannaPharmaRx security.